News

Eli Lilly is shelling out up to $690 million for access to Hanmi Pharmaceutical’s experimental BTK inhibitor HM71224, which is being developed for the treatment of autoimmune and other diseases. 

Pharma companies are trying to be patient centric but it’s not their fault they can’t fully achieve it, a US-based e-patient and research advocate has told PharmaTimes Digital. 

Access to cancer drugs in Australia is coming to a head after a bitter tit for tat over a pharma push to fast-track oncology treatment. 

Budget Day and UK Chancellor George Osborne has come under fire for largely omitting the NHS. 

Immunotherapy firm Cell Medica has been granted orphan drug status in the USA for its drug to treat rare lymphomas. 

The UK Government is spearheading a $100 million Dementia Discovery Fund in collaboration with Alzheimer’s Research UK and a number of major pharmaceutical companies. 

Novartis has been given the green light in Europe for Jakavi to treat a rare blood cancer. 

A $110 million lawsuit has been filed in the US against Novartis for alleged gender discrimination. 

Novartis’ generics unit Sandoz will be forking out $12.64 million to settle allegations it misrepresented drug pricing data to the US Medicare programme – the largest ever such settlement.

There has been a resurgence in life sciences financing in the UK, amounting to $2.86 billion, new figures reveal. 

It’s all change again in the fight for Salix Pharmaceuticals – last week’s $11 billion bid by Endo International has been binned in favour of rival bidder Valeant Pharmaceuticals International, which has put forward a revised $173-a-share offer. 

Children’s mental health services in England are to get a funding boost of some £1.25 billion to help address huge gaps in care that are tantamount to an “institutionalised form of cruelty”.

AstraZeneca has presented long-awaited, long-term data for its blood thinner Brilinta (ticagrelor), showing that the drug cut the risk of cardiovascular death, heart attack or stroke by around 16%, with an acceptable bleeding risk.

Merck & Co is facing yet another delay for its anaesthesia reversal drug sugammadex, as US regulators shelve an advisory meeting and announce plans for additional inspections.

Baxter’s investigational haemophilia treatment was successful in controlling bleeding episodes in a late-stage clinical trial with patients who develop inhibitors to clotting factor replacement therapies.